Epidermolysis Bullosa - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Epidermolysis Bullosa - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Epidermolysis Bullosa - Pipeline Review, H1 2015', provides an overview of the Epidermolysis Bullosa's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Epidermolysis Bullosa and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epidermolysis Bullosa pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Epidermolysis Bullosa Overview 7
Therapeutics Development 8
Pipeline Products for Epidermolysis Bullosa - Overview 8
Pipeline Products for Epidermolysis Bullosa - Comparative Analysis 9
Epidermolysis Bullosa - Therapeutics under Development by Companies 10
Epidermolysis Bullosa - Therapeutics under Investigation by Universities/Institutes 11
Epidermolysis Bullosa - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Epidermolysis Bullosa - Products under Development by Companies 15
Epidermolysis Bullosa - Products under Investigation by Universities/Institutes 16
Epidermolysis Bullosa - Companies Involved in Therapeutics Development 17
Fibrocell Science, Inc. 17
GlaxoSmithKline plc 18
InMed Pharmaceuticals Inc. 19
RegeneRx Biopharmaceuticals, Inc. 20
Scioderm, Inc. 21
Shire Plc 22
TWi Pharmaceuticals, Inc. 23
Epidermolysis Bullosa - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
diacerein - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Gene Therapy for Epidermolysis Bullosa - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Gene Therapy for Epidermolysis Bullosa - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Gene Therapy to Activate Collagen Type VII for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GMHDFCOL-7 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ICX-RHY - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
INM-750 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
RGN-137 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SD-101 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SHP-608 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Epidermolysis Bullosa - Recent Pipeline Updates 44
Epidermolysis Bullosa - Dormant Projects 49
Epidermolysis Bullosa - Discontinued Products 50
Epidermolysis Bullosa - Product Development Milestones 51
Featured News & Press Releases 51
Mar 19, 2015: Scioderm Initiates Phase 3 Registration Trial of Zorblisa (SD-101), a Novel Topical Therapy for Patients with Epidermolysis Bullosa 51
Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan 51
Feb 03, 2015: InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex 52
Jan 02, 2015: Scioderm to Present at 33rd Annual J.P. Morgan Healthcare Conference 52
Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States 53
Oct 06, 2014: Scioderm to Present Data from Phase 2b Study of Zorblisa (SD-101) at the 13th Annual BIO Investor Forum 53
Sep 09, 2014: Scioderm to Present Data from Phase 2b Study of Zorblisa (SD-101) at the debra International Congress 53
Jul 23, 2014: Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group 53
Jun 13, 2014: Fibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB) 54
May 28, 2014: Fibrocell Science Announces Plans for Process Development and Manufacturing of Genetically-modified Cell Therapy for Rare Disease, RDEB 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Number of Products under Development for Epidermolysis Bullosa, H1 2015 8
Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Epidermolysis Bullosa - Pipeline by Fibrocell Science, Inc., H1 2015 17
Epidermolysis Bullosa - Pipeline by GlaxoSmithKline plc, H1 2015 18
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc., H1 2015 19
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 20
Epidermolysis Bullosa - Pipeline by Scioderm, Inc., H1 2015 21
Epidermolysis Bullosa - Pipeline by Shire Plc, H1 2015 22
Epidermolysis Bullosa - Pipeline by TWi Pharmaceuticals, Inc., H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Epidermolysis Bullosa Therapeutics - Recent Pipeline Updates, H1 2015 44
Epidermolysis Bullosa - Dormant Projects, H1 2015 49
Epidermolysis Bullosa - Discontinued Products, H1 2015 50